literature

HIV mutation literature information.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

PMID: 29566538 2018 Antiviral chemistry & chemotherapy

Method: Plasma samples contained a median of 3 [Q1-Q3: 2-4] NNRTI-associated drug resistance mutations which included A98G, L100I, K101E/H, K103N/S, V106M, V108I, E138A/K, V179D/E Y181C, Y188L/C, G190A, H221Y, P225H, F227L, and M230L.

[Genetic analysis of the mutations in HIV-1 infected population in Ecuador].

PMID: 29652972 2018 Revista chilena de infectologia

Abstract: Results The most frequent mutations were M184V/I, K101E/P/H, K103N/S, D30N, M46L/I, I54L/M, V82T/F/A/S/L and L90M in adults and F77L, K103N/S, M46L/I, V82T/F/A/S/L and L90M in children.

HIV-1 transmitted drug resistance in Slovenia and its impact on predicted treatment effectiveness: 2011-2016 update.

PMID: 29698470 2018 PloS one

Discussion: Equally fit are K103N, K103S, and Y181C mutations, which were detected in four individuals from Slovenia.

Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.

PMID: 30314470 2018 BMC infectious diseases

Discussion: The K103 N/S mutation was documented in most genotypic sequences, due to the frequent use of EFV as the primary NNRTI in the first-line therapy for more than a decade in Brazil.

Prevalence of HIV-1 pretreatment drug resistance among treatment naive pregnant women in Bissau, Guinea Bissau.

PMID: 30379960 2018 PloS one

Abstract: Four carried mutations exclusively linked to non-nucleoside reverse transcriptase inhibitors (NNRTIs) (K103N, K103N/S) and one carried mutations to both NNRTIs (G190S, K101E) and nucleoside reverse transcriptase inhibitors (NRTIs) (M184V).

Result: Four carried mutations towards NNRTI only (K103N and K103N/S) and one carried mutations to both NNRTI (G190S, K101E) and

PMID: 29732898 2018 AIDS research and human retroviruses

Abstract: The most frequent WHO-defined DRMs were NRTI: codon T215 (3.0%), NNRTI: K103N/S (4%), and PI: L90 (1%

Result: Analysis of the three most prevalent NNRTI mutations is shown in Figure 6; the prevalence of the K103N/S mutation continued to increase until 2008 (6% in 2008) and then declined in prevalence in 2009 to 3%.

Result: The most prevalent NNRTI mutation was K103N/S with 4%, 95% CI: 3.7%-5.0%.

Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naive persons in rural western Kenya.

PMID: 28178281 2017 PloS one

Abstract: Predominant TDR mutations in the reverse transcriptase included K103N/S (4.6%) and M184V (2.3%); only M46I/L (1.1%) occurred in the protease.

Result: The dominant TDRMs in the RT gene were K103N/S (n = 4, 4.6%) and M184V (n = 2, 2.3%), while in the PR gene only M46I/L (n = 1, 1.1%) occurred.

Table: K103S

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).

PMID: 28891788 2017 HIV clinical trials

Method: Primary NNRTI-R substitutions assessed were V90I, A98G, L100I, K101E/H/P, K103N/S, V106A/I/M, V108I, E138A/G/K/Q/R, V179D/F/L/T, Y181C/I/V, Y188C/H/L, G190A/E/Q/S, H221Y, P225H, F227C, and M230I/L in RT.

HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China.

PMID: 28114955 2017 AIDS research and therapy

Table: K103N/S

Table: K103S

Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China.

PMID: 28099515 2017 PloS one

Table: K103S